RSS-Feed abonnieren
DOI: 10.1055/s-0039-1697600
Cost Analysis of Transfusion Therapy in Coronary Artery Surgery
Abstract
Background In patients undergoing coronary artery bypass grafting (CABG), wide variability in transfusion rate (7.8% to 92.8%) raises the question of the amount of unnecessary transfusions. The aim of the study was (1) to identify CABG patients at low risk of bleeding to whom transfusion treatment should be avoided and (2) to calculate the amount of possible cost savings that would be achieved by avoiding transfusion in low bleeding risk patients.
Methods This retrospective observational study enrolled patients undergoing isolated elective CABG from January 2010 to January 2018. Patients were divided with respect to the presence of excessive bleeding and transfusion costs were compared between the two groups. Predictors for postoperative excessive bleeding were defined and multivariable logistic regression analysis and risk modeling were performed. The use of a model to predict patients at low risk of bleeding allowed for the estimation of transfusion cost savings assuming the patients who were found to be at low risk of bleeding should not be transfused.
Results A total of 1,426 patients were enrolled in the analysis. Of those, 28.3% had excessive postoperative bleeding. The multivariate logistic regression analysis model was developed to identify/predict patients without excessive bleeding (receiver operating characteristic curve analysis, area under the curve 72.3%, p < 0.001). When applied to the existing database, the use of the developed model identifying patients at low risk of bleeding may result in a 39.1% reduction of transfusions. Specifically, cost savings would be 48.2% for packed red blood cells, 38.9% for fresh frozen plasma, 10.9% for platelets concentrate, and 17.9% for fibrinogen concentrate.
Conclusion The clinical and economic burdens associated with unnecessary transfusions are significant. Avoiding transfusion in CABG patients found to be at low risk of bleeding may result in significant reduction of transfusion rate and transfusion-associated costs.
Keywords
coronary artery bypass grafting - surgery - complications - health economics - cost analysis - blood transfusionAuthors' Contribution
M.P., M.P., M.P., V.K., V.V., K.G., and B.B.: Contributed most to the work, including drafting the article and revising it critically for important intellectual content.
M.P., M.P., M.P., B.G.C., V.M., V.V., K.G., and B.B.: Substantial contributions to the conception or design of the work.
M.P., M.P., M.P., B.G.C., V.M., H.G., V.V., K.G., and B.B.: Literature overview, data acquisition, analysis, and interpretation of data.
M.P., M.P., M.P., B.G.C., M.R., D.D., V.K., V.M., H.G., V.V., K.G., and B.B.: Final approval of the version.
M.P., M.P., M.P., B.G.C., M.R., D.D., V.K., V.M., H.G., V.V., K.G., and B.B.: Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
M.P., M.P., V.K., V.M., V.V., K.G., and B.B.: Figures.
M.P., M.P., M.P., B.G.C., M.R., D.D., V.K., V.M., H.G., V.V., K.G., and B.B.: Drafting the work for important intellectual content.
* Petricevic Mirna and Petricevic Mate are co-first authors.
Publikationsverlauf
Eingereicht: 27. Mai 2019
Angenommen: 05. August 2019
Artikel online veröffentlicht:
11. Oktober 2019
© 2019. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany